It seemed too good to be true. A diamond-rich, corruption-free, democratic, prosperous, and peaceful African country with a tradition of peaceful transfer of presidential power (the incumbent president voluntarily leaves office a year before the next general election). It was.
FOR years, African countries have paid exorbitant amounts for pharmaceuticals developed in the US, including drugs such as AZT, which is used to treat Aids. The reasoning was always that it cost pharmaceutical companies upwards of US$1bn to create these drugs — and these costs must be recouped.But a new investigation of the murky tax breaks used by the industry tell another story entirely.